Please login to the form below

Not currently logged in
Email:
Password:

Blincyto

This page shows the latest Blincyto news and features for those working in and with pharma, biotech and healthcare.

Xencor’s Novartis-partnered bispecific on hold after patient deaths

Xencor’s Novartis-partnered bispecific on hold after patient deaths

Amgen’s already-approved Blincyto (blinatumomab) for acute lymphoblastic leukaemia (ALL) drug. ... Blincyto is a bispecific that targets CD3 and CD19 and lists CRS in a boxed warning on the label.

Latest news

More from news
Approximately 5 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Pharma deals in September 2015 Pharma deals in September 2015

    Amgen, has had success with in-house bispecifics already, such as acute lymphoblastic leukaemia (ALL) treatment, Blincyto; the in-developme nt acute myeloid leukaemia (AML) therapy AMG 330; and multiple myeloma

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics